Tanium Converge Travels to London and Paris
13.4.2023 10:00:00 EEST | Business Wire | Press release
Tanium, the industry’s only provider of converged endpoint management (XEM), today announced the beginning of the Converge World Tour 2023, a six-city series of its global user conference. The kickoff event in London will be held Tuesday, 18th April, at the London Landmark Hotel, with a show at the Campus Cyber, Paris to follow on Thursday where Tanium will showcase its innovation spotlight, including its product roadmap and future enhancements to the XEM platform.
Converge is Tanium’s flagship event that brings together industry specialists, peers, and partners to share strategies for leveraging converged endpoint management (XEM) to improve organizational cybersecurity readiness and response. There’s no better opportunity for IT and security practitioners to discover new ways of driving value to their boards and accelerating business initiatives than to gain outside perspectives and hear first-hand experiences from those on the frontline of the cyber landscape.
“Tanium’s commitment is first, last, and always to our customers, and we are grateful to have such a strong and extensive partner ecosystem that is equally committed to maximizing the value our customers achieve from their investments in Tanium,” said Steve Daheb, chief marketing officer at Tanium. “Join us in Paris and London to see why Forrester reports Tanium driving ROI of more than 200% for customers, why eight of top 10 global financial institutions and seven of the top 10 global retailers trust Tanium to maximize their ROI and simplify their technology environments while defending their organizations against emerging threats and expanding their knowledge of managing risk, securing technology, and unlocking innovation at scale from a single intuitive platform.”
Join Tanium for a dynamic keynote experience, featuring top executives and industry experts who will enable you to:
- Glimpse into the future with Tanium—including the global unveiling of a new offering designed to improve overall work productivity, increase employee satisfaction, and lower IT support costs
- Understand the use and benefits of XEM with category creator Steve Daheb
- Gain insights from an intimate fireside chat with customer success champion Charles Ross
- Explore the many ways Microsoft and Tanium work better together to improve cyber resilience with partner facilitator Mike Fiorina
- Get a firsthand look at real customer successes with a panel featuring Aviva and Fraser’s Group and partner enablement executive Todd Palmer
- Participate in peer-based breakout sessions across executive-, technical-, and partner-focused tracks
WHO : IT and security professionals from across Europe; Tanium’s newly appointed CEO, Dan Streetman, and members of his executive team; Forrester analyst Andrew Hewitt; Frasers Group’s Matthew Wilmot; Aviva’s Marc Hasketh-Boston; and Tanium customers and partners that include EY, PwC, Armadillo Managed Services, Computacenter, SCC, EndpointX, Pointwire, BlueTrusty, Capgemini, Cegedim, DOUNYX, EY, I-TRACING, Orange Cyberdefense, and more
WHAT : Tanium Converge London and Tanium Converge Paris, featuring spotlights on current trends, industry best practices, expert-led sessions, breakout discussions, and hands-on labs
WHER E: The Landmark London Hotel and the Campus Cyber in Paris–La Defense
WHEN : Tuesday, 18th April 2023 (London) and Thursday, 20th April (Paris)
HOW : The shows are sold out, but you can still register to secure your place on the waitlist or join us for mainstage public sessions on demand by signing up for the London show or the Paris event. We look forward to seeing you there!
About Tanium
Tanium, the industry’s only provider of converged endpoint management (XEM), is the reference platform of choice to manage complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005318/en/
Contact information
Lindsey Lockhart
Tanium PR
press@tanium.com
+ 1 214.562.1521
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom